Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/178)
-
Patent number: 8541400Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.Type: GrantFiled: August 4, 2005Date of Patent: September 24, 2013Assignee: Camurus ABInventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg
-
Publication number: 20130243861Abstract: The present invention provides for press-coated tablets of prednisone comprising a core comprising prednisone and a coating around the core. The present invention particularly discloses thickness of the coating applied to core having a convex shape for chronotherapeutic use. The present invention also provides for a process for preparing a press-coated tablet of prednisone and a method for treating conditions or pathology, the symptoms of which occur early in the morning.Type: ApplicationFiled: March 14, 2013Publication date: September 19, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan ROY, Sushrut Krishnaji KULKARNI, Ajaykumar HANDA, Ketan Tulsidas SAVJANI
-
Publication number: 20130244990Abstract: The present disclosure provides methods for determining risk for depression, as well as compositions for use in such methods.Type: ApplicationFiled: November 30, 2012Publication date: September 19, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventor: The Board of Trustees of the Leland Stanford Junior University
-
Publication number: 20130231317Abstract: The DHEA bioadhesive controlled release gel includes DHEA mixed in a polymeric gel for the purpose of treating atrophic vaginitis, vaginal dryness, dyspareunia, itching, burning, irritation, increase in pH and decreased vaginal flora. The gel adheres to vaginal tissue and protects the DHEA from systemic absorption, which prevents leakage, loss of DHEA, and elevated levels of systemic DHEA. The gel is configured to slowly erode over time so as to deliver a predetermined dose of DHEA to vaginal tissue and thereby promote local intracellular conversion to estrogens, androgens and progesterone so that normal levels of fluid in the vagina is produced. The gel also acts as a moisturizer. An adjustable applicator may also be provided to insure proper placement and dose of the DHEA.Type: ApplicationFiled: October 19, 2011Publication date: September 5, 2013Inventor: Michael S. Riepl
-
Patent number: 8524693Abstract: The invention relates to processes for obtaining steroids with a spirolactone group in position 17, particularly to industrially obtaining 6?,7?; 15?,16?-dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, commonly known as Drospirenone, as well as to intermediates useful in said process.Type: GrantFiled: June 16, 2010Date of Patent: September 3, 2013Assignee: Crystal Pharma, S.A.Inventors: Jesús Miguel Iglesias Retuerto, Luis Gerardo Gutiérrez Fuentes, Antonio Lorente Bonde-Larsen
-
Publication number: 20130225544Abstract: The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is —C13H25O or —C14H27O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone Cavg t12-t24 that is within about 35% to about 70% of the mean serum testosterone Cavg t0-t24.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: LIPOCINE INC.Inventor: Lipocine Inc.
-
Patent number: 8518921Abstract: Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or neutered animals.Type: GrantFiled: July 2, 2012Date of Patent: August 27, 2013Assignee: Nestec SAInventor: Yuanlong Pan
-
Publication number: 20130210789Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 15, 2013Applicants: Laboratoire Besins International, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130210790Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 15, 2013Applicants: LABORATOIRE BESINS INTERNATIONAL, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130210791Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 15, 2013Applicants: LABORATOIRE BESINS INTERNATIONAL, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130210783Abstract: Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of Alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury. Also provided are methods for ameliorating a sleep disorder; for improving cognitive functioning; for predicting a predisposition to suicide, suicidal ideation, and/or suicidal behavior; and for ameliorating a neurodegenerative disorder. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.Type: ApplicationFiled: August 31, 2012Publication date: August 15, 2013Applicant: Duke UniversityInventors: Christine E. Marx, Jed E. Rose
-
Patent number: 8507467Abstract: A transdermally absorbable preparation comprises a natural type sex hormone, a polyoxyethylene oleyl ether having a molar number of ethylene oxide units added of 20, at least two kinds of oily ingredients selected from the group consisting of diisopropyl adipate, cetyl alcohol, benzyl alcohol, and propylene glycol dicaprate, a polyhydric alcohol, and ethanol.Type: GrantFiled: September 10, 2008Date of Patent: August 13, 2013Assignee: Shiseido Company, Ltd.Inventors: Rakan Matsui, Osamu Ueda
-
Publication number: 20130203720Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicants: LABORATOIRE BESINS INTERNATIONAL, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130195926Abstract: The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.Type: ApplicationFiled: December 4, 2012Publication date: August 1, 2013Applicant: The General Hospital CorporationInventor: The General Hospital Corporation
-
Publication number: 20130196959Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Temple University - Of The Commonwealth System of Higher EducationInventor: Temple University - Of The Commonwealth System of Higher Education
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent number: 8492369Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.Type: GrantFiled: April 12, 2010Date of Patent: July 23, 2013Assignee: Clarus Therapeutics IncInventors: Robert E. Dudley, Panayiotis P. Constantinides -
Patent number: 8492505Abstract: The present invention relates to a process for the preparation of branched biodegradable polymers comprising of the steps of: (a) preparing a macromonomer by ring-opening polymerization of at least one cyclic ester, cyclic carbonate, and/or cyclic carboxyanhydride in the presence of a branching agent and optionally a catalyst; and (b) subsequent polycondensation of the macromonomer, to a process for the preparation of a macromonomer by ring-opening polymerization of at least one cyclic ester, carbonate and/or N-carboxyanhydride in the presence of a defined branching agent and optionally a catalyst, according to step (a), and to the prepared macromonomer and branched biodegradable polymer and their uses.Type: GrantFiled: May 31, 2006Date of Patent: July 23, 2013Assignee: University of TwenteInventors: Jan Feijen, Zhiyuan Zhong, Pieter Jelle Dijkstra
-
Patent number: 8486925Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: October 5, 2011Date of Patent: July 16, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Miller
-
Patent number: 8486374Abstract: A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.Type: GrantFiled: January 14, 2008Date of Patent: July 16, 2013Assignee: Foamix Ltd.Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Alex Besonov, David Schuz, Tal Berman, Jorge Danziger, Rita Keynan, Ella Zlatkis
-
Patent number: 8476253Abstract: Compounds or pharmacologically acceptable salts thereof are provided. In various embodiments the compounds have an antagonistic effect on a neurokinin NK1 receptor, a neurokinin NK2 receptor, and a muscarine M3 receptor. The compounds are useful as therapeutic agents for bronchial asthma, chronic obstructive pulmonary disease, or the like.Type: GrantFiled: September 16, 2011Date of Patent: July 2, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Takuya Ikeda, Takanori Yamazaki, Hiroshi Tsuchida
-
Patent number: 8470371Abstract: Polymeric micellar clusters formed from amphiphilic carbohydrate polymers and their uses in formulating drugs is disclosed, and in particular the finding that amphiphilic carbohydrate polymers are capable of self assembling to form micellar clusters in which the carbohydrate amphiphiles aggregate into hierarchically organized micellar clusters of individual aggregates. The micellar clusters may be transformed into stable nanoparticles with drugs, especially hydrophobic drugs that have poor aqueous solubility, and may improve the transfer of hydrophobic drugs across biological barriers.Type: GrantFiled: August 8, 2007Date of Patent: June 25, 2013Assignee: University College LondonInventors: Ijeoma F. Uchegbu, Andreas G. Schatzlein, Xueliang Hou
-
Patent number: 8470370Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.Type: GrantFiled: November 28, 2012Date of Patent: June 25, 2013Assignees: Aegis Therapeutics, LLC, The UAB Research FoundationInventors: Edward T. Maggio, Elis Meezan, Dennis J. Pillion, Sarah L. Morgan, Joe Baggott
-
Publication number: 20130157988Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.Type: ApplicationFiled: April 7, 2011Publication date: June 20, 2013Applicants: EMORY UNIVERSITY, HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, THE RESEARCH FOUNDATION OF STATE OF NEW YORKInventors: Huw Davies, Debashis Ghosh, Daniel Morton
-
Patent number: 8466139Abstract: The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7?-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17?-diol, more particularly to a formulation adapted for administration by injection containing the compound 7?-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17?-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.Type: GrantFiled: September 4, 2012Date of Patent: June 18, 2013Assignee: AstraZeneca ABInventors: John R Evans, Rosalind U Grundy
-
Patent number: 8466138Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: October 5, 2011Date of Patent: June 18, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Miller
-
Patent number: 8466137Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: July 11, 2011Date of Patent: June 18, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20130149344Abstract: A pleasure enhancing condom comprises a tubular member being configured to encase an organ being operable for penetration and or contact during a sexual activity. A chemical composition is disposed about at least a portion of the exterior surface of the tubular member. The chemical composition comprises one or more hormones being operable for transferring to a contacting individual to enhance the sexual activity.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventor: Arthur Ruppin
-
Patent number: 8460641Abstract: An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.Type: GrantFiled: August 31, 2005Date of Patent: June 11, 2013Assignee: Stiefel Research Australia Pty LtdInventors: Maria Graziella Larm, Ronald Harding, Michael Johnston, Albert Zorko Abram, Prema Vijayakumar, Phoebe Sun
-
Publication number: 20130143847Abstract: The present disclosure relates generally to methods and compositions for treating symptoms of Parkinson's disease and/or other movement disorders. More particularly, the present disclosure describes a method for treating symptoms of Parkinson's disease and related disorders by administering a composition comprising one or more of the following active agents; estradiol, estriol, testosterone, and 19-nortestosterone. In addition, the compositions of the present invention can be used for enhancing or optimizing the effectiveness of neural stimulation in treating the symptoms of movement disorders such as Parkinson's disease.Type: ApplicationFiled: November 19, 2012Publication date: June 6, 2013Inventor: Ellis L. Kline
-
Publication number: 20130143851Abstract: Solutions of testosterone for oromucosal administration providing an increase in serum testosterone levels in subjects deficient in endogenous testosterone levels, and therapeutic methods for providing an increase in serum testosterone levels and methods for treating a disease or a symptom associated with deficient endogenous levels of testosterone.Type: ApplicationFiled: August 9, 2011Publication date: June 6, 2013Applicant: INNOTESTO BVBAInventor: Franciscus Wilhelmus Henricus Maria Merkus
-
Publication number: 20130143850Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.Type: ApplicationFiled: June 16, 2011Publication date: June 6, 2013Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Nicolette Farman, Francine Behar-Cohen, Frédéric Jaisser
-
Publication number: 20130136784Abstract: A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora.Type: ApplicationFiled: January 23, 2013Publication date: May 30, 2013Inventor: Robert J. Staab
-
Patent number: 8449867Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.Type: GrantFiled: June 25, 2009Date of Patent: May 28, 2013Assignee: Stiefel Research Australia Pty LtdInventors: Maria Graziella Larm, Ronald Harding, Michael Johnston, Albert Zorko Abram, Prema Vijayakumar, Phoebe Sun
-
Patent number: 8450299Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: GrantFiled: June 8, 2012Date of Patent: May 28, 2013Assignee: Teva Womans's Health, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
-
Publication number: 20130122061Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: ApplicationFiled: December 13, 2012Publication date: May 16, 2013Applicant: JAGOTEC AGInventor: Jagotec AG
-
Publication number: 20130116217Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration, and include effects on stroke and TBI.Type: ApplicationFiled: December 21, 2012Publication date: May 9, 2013Applicant: THE POPULATION COUNCIL, INC.Inventor: The Population Council, Inc.
-
Publication number: 20130116222Abstract: A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Inventors: Charles G. ARNOLD, Agis KYDONIEUS, Thomas M. ROSSI, Alfred F. ALTOMARI
-
Patent number: 8435944Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.Type: GrantFiled: June 2, 2006Date of Patent: May 7, 2013Assignee: Acrux DDS Pty Ltd.Inventors: Tony Dipietro, Andrew Humberstone, Igor Gonda, Adam Watkinson, Kerrie Setiawan, Nina Wilkins
-
Patent number: 8435973Abstract: Substituted steroid compounds which represent selective inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulfatase enzymes and/or requiring lowering of the endogenous 17?-estradiol concentration.Type: GrantFiled: September 28, 2010Date of Patent: May 7, 2013Assignee: Abbott Products GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Michael Weske, Pasi Koskimies, Lila Pirkkala
-
Publication number: 20130102578Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.Type: ApplicationFiled: December 17, 2012Publication date: April 25, 2013Applicant: UMECRINE ABInventor: Umecrine AB
-
Publication number: 20130102577Abstract: The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.Type: ApplicationFiled: April 11, 2011Publication date: April 25, 2013Applicant: The Research Foundation of the State University of New YorkInventors: William G. Kerr, John D. Chisholm
-
Patent number: 8415332Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: GrantFiled: August 17, 2007Date of Patent: April 9, 2013Assignee: Teva Woman's Health, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
-
Publication number: 20130079315Abstract: A suspension comprising an ophthalmic active that has a solubility in water at 25° C. and a pH of 7 of less than 0.1 times the concentration of the active in mg/mL in the suspension, the ophthalmic active suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, G?>G? and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 mL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G?>G? and the tear mixture has a yield value of less than 0.1 Pa.Type: ApplicationFiled: August 31, 2012Publication date: March 28, 2013Inventor: Martin J. Coffey
-
Publication number: 20130078286Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: ApplicationFiled: November 9, 2012Publication date: March 28, 2013Applicant: MSD Oss B.V.Inventor: MSD Oss B.V.
-
Publication number: 20130079311Abstract: The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second container having at least one second inactive agent. The kits of the invention are also useful for compounding veterinary pharmaceuticals.Type: ApplicationFiled: September 27, 2012Publication date: March 28, 2013Applicant: CutisPharma, Inc.Inventor: Indu Muni
-
Publication number: 20130072466Abstract: Provided is a composition containing placenta extracts as active ingredients. Placenta extracts are natural substances extracted from placentas of livestock and show effects that can replace steroids and reduce adverse effects of steroids, so that placenta extracts have a wide range of applications including contraceptives, anti-osteoporosis drugs, anti-anemic drugs, therapeutic agents for wasting diseases of muscular atrophy, agents for treating sexual dysfunction, therapeutic agents for wounds, and adipocyte differentiation stimulating agents for improving meat quality of livestock, etc.Type: ApplicationFiled: February 21, 2011Publication date: March 21, 2013Applicant: Industry-Academic Cooperation Foundation, Yeungnam UniversityInventors: In Ho Choi, Dong Mok Lee, Eun Ju Lee, Ki-Ho Lee, Yong-Pil Cheon, Tae-Hoon Chun
-
Publication number: 20130065853Abstract: The invention encompasses compositions and methods for use in preventing pregnancy.Type: ApplicationFiled: March 30, 2012Publication date: March 14, 2013Applicant: THE WASHINGTON UNIVERSITYInventors: Kelle H. Moley, Antonina I. Frolova
-
Publication number: 20130059827Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.Type: ApplicationFiled: May 14, 2012Publication date: March 7, 2013Applicant: Trimel Pharmaceuticals CorporationInventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul Maes
-
Publication number: 20130059826Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.Type: ApplicationFiled: August 15, 2012Publication date: March 7, 2013Applicant: CyDex Pharmaceuticals, Inc.Inventors: James D. PIPKIN, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher